404 related articles for article (PubMed ID: 33188693)
1. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials.
Eckardt KU; Agarwal R; Farag YM; Jardine AG; Khawaja Z; Koury MJ; Luo W; Matsushita K; McCullough PA; Parfrey P; Ross G; Sarnak MJ; Vargo D; Winkelmayer WC; Chertow GM
Nephrol Dial Transplant; 2021 Nov; 36(11):2039-2048. PubMed ID: 33188693
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.
Eckardt KU; Agarwal R; Aswad A; Awad A; Block GA; Bacci MR; Farag YMK; Fishbane S; Hubert H; Jardine A; Khawaja Z; Koury MJ; Maroni BJ; Matsushita K; McCullough PA; Lewis EF; Luo W; Parfrey PS; Pergola P; Sarnak MJ; Spinowitz B; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Zwiech R; Chertow GM
N Engl J Med; 2021 Apr; 384(17):1601-1612. PubMed ID: 33913638
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics.
Chertow GM; Pergola PE; Agarwal R; Block GA; Farag YMK; Jardine AG; Koury MJ; Luo W; Khawaja Z; Lewis EF; Matsushita K; McCullough PA; Parfrey PS; Wittes J; Walters KA; Tseng C; Lin T; Sarnak MJ; Vargo DL; Winkelmayer WC; Eckardt KU
Am Heart J; 2021 May; 235():1-11. PubMed ID: 33129989
[TBL] [Abstract][Full Text] [Related]
4. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.
Chertow GM; Pergola PE; Farag YMK; Agarwal R; Arnold S; Bako G; Block GA; Burke S; Castillo FP; Jardine AG; Khawaja Z; Koury MJ; Lewis EF; Lin T; Luo W; Maroni BJ; Matsushita K; McCullough PA; Parfrey PS; Roy-Chaudhury P; Sarnak MJ; Sharma A; Spinowitz B; Tseng C; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Eckardt KU;
N Engl J Med; 2021 Apr; 384(17):1589-1600. PubMed ID: 33913637
[TBL] [Abstract][Full Text] [Related]
5. Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis.
Sarnak MJ; Agarwal R; Boudville N; Chowdhury PCP; Eckardt KU; Gonzalez CR; Kooienga LA; Koury MJ; Ntoso KA; Luo W; Parfrey PS; Vargo DL; Winkelmayer WC; Zhang Z; Chertow GM
Nephrol Dial Transplant; 2023 Sep; 38(10):2358-2367. PubMed ID: 37096396
[TBL] [Abstract][Full Text] [Related]
6. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.
Martin ER; Smith MT; Maroni BJ; Zuraw QC; deGoma EM
Am J Nephrol; 2017; 45(5):380-388. PubMed ID: 28343225
[TBL] [Abstract][Full Text] [Related]
7. Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies.
Akizawa T; Taguchi M; Matsuda Y; Iekushi K; Yamada T; Yamamoto H
BMJ Open; 2019 Jun; 9(6):e026602. PubMed ID: 31203241
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study.
Nangaku M; Kondo K; Ueta K; Kokado Y; Kaneko G; Matsuda H; Kawaguchi Y; Komatsu Y
Nephrol Dial Transplant; 2021 Aug; 36(9):1731-1741. PubMed ID: 33650630
[TBL] [Abstract][Full Text] [Related]
9. A phase 3, open-label, single-arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis-stimulating agents.
Nangaku M; Kondo K; Takabe S; Ueta K; Tandai T; Kawaguchi Y; Komatsu Y
Ther Apher Dial; 2022 Feb; 26(1):45-54. PubMed ID: 34115437
[TBL] [Abstract][Full Text] [Related]
10. Factors affecting responsiveness of vadadustat in patients with anemia associated with chronic kidney disease: a post-hoc subgroup analysis of Japanese phase 3 randomized studies.
Nangaku M; Ueta K; Nishimura K; Sasaki K; Hashimoto T
Clin Exp Nephrol; 2024 May; 28(5):391-403. PubMed ID: 38530490
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease.
Koury MJ; Agarwal R; Chertow GM; Eckardt KU; Fishbane S; Ganz T; Haase VH; Hanudel MR; Parfrey PS; Pergola PE; Roy-Chaudhury P; Tumlin JA; Anders R; Farag YMK; Luo W; Minga T; Solinsky C; Vargo DL; Winkelmayer WC
Am J Hematol; 2022 Sep; 97(9):1178-1188. PubMed ID: 35751858
[TBL] [Abstract][Full Text] [Related]
12. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.
Pergola PE; Spinowitz BS; Hartman CS; Maroni BJ; Haase VH
Kidney Int; 2016 Nov; 90(5):1115-1122. PubMed ID: 27650732
[TBL] [Abstract][Full Text] [Related]
13. The ASCEND-ND trial: study design and participant characteristics.
Perkovic V; Blackorby A; Cizman B; Carroll K; Cobitz AR; Davies R; DiMino TL; Jha V; Johansen KL; Lopes RD; Kler L; Macdougall IC; McMurray JJV; Meadowcroft AM; Obrador GT; Solomon S; Taft L; Wanner C; Waikar SS; Wheeler DC; Wiecek A; Singh AK
Nephrol Dial Transplant; 2022 Oct; 37(11):2157-2170. PubMed ID: 34865143
[TBL] [Abstract][Full Text] [Related]
14. Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open-label study in Japan.
Nangaku M; Kondo K; Takabe S; Ueta K; Kaneko G; Otsuka M; Kawaguchi Y; Komatsu Y
Ther Apher Dial; 2021 Oct; 25(5):642-653. PubMed ID: 33283981
[TBL] [Abstract][Full Text] [Related]
15. Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies.
Yamamoto H; Taguchi M; Matsuda Y; Iekushi K; Yamada T; Akizawa T
BMJ Open; 2019 Jun; 9(6):e026704. PubMed ID: 31203242
[TBL] [Abstract][Full Text] [Related]
16. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
Singh AK; Carroll K; Perkovic V; Solomon S; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Więcek A; Blackorby A; Cizman B; Cobitz AR; Davies R; Dole J; Kler L; Meadowcroft AM; Zhu X; McMurray JJV;
N Engl J Med; 2021 Dec; 385(25):2325-2335. PubMed ID: 34739194
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of vadadustat compared to darbepoetin alfa on anemia in patients with chronic kidney disease: a meta-analysis.
Huang Q; Liao Z; Liu X; Xia Y; Wang J
Int Urol Nephrol; 2023 Feb; 55(2):325-334. PubMed ID: 35960479
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial.
Singh AK; Cizman B; Carroll K; McMurray JJV; Perkovic V; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Wiecek A; Stankus N; Strutz F; Blackorby A; Cobitz AR; Meadowcroft AM; Paul G; Ranganathan P; Sedani S; Solomon S
JAMA Intern Med; 2022 Jun; 182(6):592-602. PubMed ID: 35377393
[TBL] [Abstract][Full Text] [Related]
19. Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents.
Haase VH; Chertow GM; Block GA; Pergola PE; deGoma EM; Khawaja Z; Sharma A; Maroni BJ; McCullough PA
Nephrol Dial Transplant; 2019 Jan; 34(1):90-99. PubMed ID: 29672740
[TBL] [Abstract][Full Text] [Related]
20. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
